Skip to main content
NIH funding notice RFA-AI-21-039

Consortium for Innovative HIV/AIDS Vaccine and Cure Research (UM1 Clinical Trial Not Allowed)

Closed on August 4, 2021.

Posted
May 7, 2021
Close date
August 4, 2021
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $11,534,306 in first-year total cost, median $5,767,153.

Most frequent study sections

  1. Special Emphasis Panel[ZAI1 JBS-A (J1)]2

Most frequent institutions

  1. DUKE UNIVERSITY1
  2. EMORY UNIVERSITY1
Competing awards under RFA-AI-21-039 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2022B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection1UM1AI169662-01AMARA, RAMA RAOHUNTER, ERICEMORY UNIVERSITY, GA$5,814,430ZAI1
2022SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens1UM1AI169633-01FERRARI, GUIDOWILLIAMS, WILTON BDUKE UNIVERSITY, NC$5,719,876ZAI1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-AI-21-039: Consortium for Innovative HIV/AIDS Vaccine and Cure Research (UM1 Clinical Trial Not Allowed) | ScienceDex | ConductScience